

# Schedule of Accreditation



Organisation Name	National Virus Reference Laboratory
Trading As	
INAB Reg No	326MT
Contact Name	Eimear Malone
Address	University College Dublin, Belfield, Dublin, D4
Contact Phone No	01-7161319
Email	eimear.malone@ucd.ie
Website	
Accreditation Standard	EN ISO 15189
Standard Version	2022
Date of award of accreditation	09/09/2014
Scope Classification	Microbiology and virology
Services available to the public <sup>1</sup>	No

<sup>1</sup> Refer to document on interpreting INAB Scopes of Accreditation

Sites from which accredited services are delivered		
(the detail of the accredited services delivered at each site are on the Scope of Accreditation)		
	Name	Address
1	NVRL Satellite Laboratory Backweston (NSLB)	Lab 5, Dept. of Agriculture Food and the Marine, Backweston Laboratory Campus, Ballymadeer, Celbridge, Celbridge, Kildare, Ireland, W23X3PH
2	Head Office	University College Dublin, Belfield, Dublin, D4

# Scope of Accreditation

## Head Office

### Microbiology and Virology

Category: A

Medical pathology field - Test	Test/assay	Specimen Type	Equipment/Technique	Method (CE/Non-CE/In house developed/based on standard method)	Range of measurement	Std. ref & SOP
1015 Detection and/or identification of bacterial, parasite, fungal and viral nucleic acids - .03 Nucleic acid amplification tests, CE marked commercial systems	Altona RealStar JCV PCR assay	Serum, plasma and CSF	ABI 7500 FAST Analyser	CE Marked	Detected IU/ml and Not Detected	LP/MVIR/152
	Altona SARS-CoV-2 RT-PCR	Respiratory swabs	MagNa Pure 96	CE Marked	Qualitative	LP-CL3-065
	AltoStar® HAV RT-PCR	Stool, Serum	Taqman 7500	CE	Detected/Not Detected	LP/MVIR/243
	Aptima Mycoplasma Genitalium Assay	Aptima collection device - Anal swab, endocervical swab, urine	Hologic Panther System	CE Marked	Qualitative	VAL/MVIR/225 and LP/MVIR/186
	BioFire Filmarray Respiratory Panel	Respiratory Aspirates, BALS, Respiratory Swabs	Biofire Filmarray Instrument	CE Marked Commercial	Qualitative	LP/MVIR/183

BioFire® Respiratory Panel 2.1 plus	Nasopharyngeal Swab	BioFire FilmArray	CE	Detected/Not Detected	LP/MVIR/183
CT/NG	Urine and swabs	Panther	CE	Not Detected RLU < 85 Equivocal 85-250 Detected 250-<4500	LP/MVIR/186
Detection of Adenovirus using the Altona RealStar Adenovirus PCR Kit 1.0	Serum/Plasma	PSH, Magnapure 96, Qiagility, Taqman 7500 FAST	CE Marked Commercial	10*3 - 10*8 copies/ml	LP/MVIR/200
Detection of viruses in CSF samples using the Altona RealStar HSV, VZV & Entero PCR kits	CSF, Serum, Plasma	EasyMAG® Automated Extractor, Qiagility	CE Marked	Detected, Not Detected	LP/MVIR/220
GeneXpert HIV-1 VL assay	Plasma	GeneXpert Dx system	CE Marked	Detected copies/ml and not detected	LP/MVIR/173
HCV II Genotyping	Human serum and plasma	Abbott real time assay	CE	> 500 IU/ml Required for Genotyping	LP/MVIR/128
HCV RNA		Abbott real time assay	CE	Quantitative Range 12-10*8 IU/ml	LP/MVIR/125
Hepatitis B Virus		Abbott real time assay	CE	Quantitative Range 10-10*9 IU/ml	LP/MVIR/135
Immunodeficiency virus type 1		Abbott real time assay	CE	Quantitative Range 40-10*7 Copies/ml	LP/MVIR/120
NxTAG Respiratory Pathogen Panel Luminex	Respiratory secretion specimens and respiratory swabs	MagNA pure 96 (Roche), MAGPIX (Luminex)	CE Marked	Detected, Negative	LP/MVIR/198
RealStar Altona HHV-6 Assay	Plasma, saliva, swab, CSF	Taqman 7500 Fast	CE Marked	Qualitative	LP/MVIR/112 and VAL/MVIR/233
RealStar Pneumocystis jirovecii PCR kit (Altona)	Sputum, BAL, Aspirate	Taqman 7500	CE	Detected/Not Detected	LP-MVIR-222
Real-Time PCR for BK virus DNA (Quantitative)	Serum, Plasma, and Urine samples	Taqman 7500	CE	Quantitative range 1000- 10*9 Copies/ml	LP/MVIR/177
Real-Time PCR for Hepatitis E Virus	Serum	Taqman 7500	CE marked with validated	Positive HEV RNA results > 1x10(4) IU/ml	LP/MVIR/160

				modification	reported quantitatively. b) Samples with a viral load greater than 1x10(10) IU/ml. this reported as > 10.0 log IU/ml. c) Positive HEV RNA results below 1x10(4) IU/ml reported as "DETECTED < 10,000 IU/ml (< 4.0 LogIU/ml)" d) Negative HEV RNA results are reported as "Not detected"	
			Taqman 7500	CE marked with validated modification	Positive HEV RNA results > 1x10(4) IU/ml reported quantitatively. b) Samples with a viral load greater than 1x10(10) IU/ml. this reported as > 10.0 log IU/ml. c) Positive HEV RNA results below 1x10(4) IU/ml reported as "DETECTED < 10,000 IU/ml (< 4.0 LogIU/ml)" d) Negative HEV RNA results are reported as "Not detected"	LP/MVIR/160
Real-time PCR for Herpes Simplex 1 and 2 virus DNA	Swabs,	Taqman 7500 analyser and ViiA 7	in-house developed	cT < 35 DETECTED cT 35-38 DETECTED at low level cT > 38, repeat		LP/MVIR/107
Real-time PCR for JC Virus DNA	CSF, Serum, Urine and Plasma	Taqman 7500	CE	Blood / CSF - quantitatively as (a) DETECTED < 2.0 Log10 IU/mL (b) If between 90 and 9e10 IU/mL then report		LP/MVIR/152

					number (c) DETECTED > 11.0 Log10 IU/mL	
			Taqman 7500	CE	Blood / CSF - quantitatively as (a) DETECTED < 2.0 Log10 IU/mL (b) If between 90 and 9e10 IU/mL then report number (c) DETECTED > 11.0 Log10 IU/mL	LP/MVIR/152
	Real-Time RT-PCR for Enterovirus and Parechovirus RNA	Stool, Swab	Taqman 7500	in-house developed	Detected cT < 38	0 LP/MVIR/134
	RT PCR for the detection and quantification of HIV type 1 (HIV-1)	Plasma	GeneXpert Instrument	CE Marked Commercial	Quantitative Copies /ml	LP/MVIR/173
	The GeneXpert HCV Viral Load Assay	Plasma	Cepheid GeneXpert IV System	CE Marked	Qualitative range reported as detected <1.08 log IU/ml. Quantitative value reported >1.0 to 8 log IU/ml.	LP-MVIR-173
		Serum and plasma	Cepheid GeneXpert	CE marked with validated modification	HCV genotypes 1-6 over the range of 10 to 100,000,000 IU/mL	LP-MVIR-173
	Trichomonas vaginalis on the Panther	Aptima Collection Device	Panther System	CE Marked Commercial	Qualitative	LP/MVIR/097
1015 Detection and/or identification of bacterial, parasite, fungal and viral nucleic acids - .04 Nucleic acid amplification tests, in house developed assays	In-House HIV Genotypic Antiretroviral Resistance Assay	Plasma	Applied Biosystems 3500 Genetic Analyser	In House	N/A	LP/MVIR/176
	Molecular Respiratory Surveillance Real-time PCR Screen	Respiratory secretion specimens and respiratory swabs	ViiA7, Taqman 7500, MagNApure 96	In house	Qualitative	LP-MVIR-215
	One-Step Real-Time	Oral Fluid, CSF, other	Qiagen, Taqman 7500	In House	Qualitative	LP/MVIR/112

	RT-PCR for the Detection of Mumps Virus	sample types are tested with an NVRL comment	FAST			
	Real-Time PCR for Adenovirus DNA	Swabs, Stool	Taqman 7500 analyser and/or ViiA 7	in-house developed	cT < 35 DETECTED cT 35-38 DETECTED at low level cT > 38, repeat	LP/MVIR/107
	Real-time PCR for the detection of Norovirus, Astrovirus, Sapovirus, Adenovirus type F, Rotavirus and Rotarix (Gastro screen)	Faecal	Roche MagNA Pure 96, ABI 7500/ViiA7	In House	Detected cT ≤35	LP/MVIR/153
	Real-Time PCR for Varicella Zoster DNA	Swabs,	Taqman 7500 analyser and ViiA 7	in-house developed	cT < 35 DETECTED cT 35-38 DETECTED at low level cT > 38, repeat	LP/MVIR/107
1015 Detection and/or identification of bacterial, parasite, fungal and viral nucleic acids - .05 Nucleotide sequencing & analysis	HBV Genotyping/Resistance	Serum/Plasma	Manual Qiagen, RT-PCR (nested), Sanger sequencing (ABI 3500Dx)	In House	>=log 3 IU/ml	LP/MVIR/193
	HCV Genotyping by Sanger Sequencing		Manual Qiagen, RT-PCR (nested), Sanger sequencing (ABI 3500Dx)	In House	>=log 4 IU/ml	LP/MVIR/197
1018 Detection of antibody response to infection using appropriate CE marked commercial techniques - .01 Particle agglutination, using CE marked commercial systems	TP-PA	Human serum and plasma	Manual	CE	Negative Indeterminate Pos 1:80, 1:160, 1:320, 1:640, 1:1280	LP/VSER/008
1018 Detection of antibody response to infection using appropriate CE marked commercial techniques - .02 Enzyme immunoassay, using CE marked commercial	Anti-HBc		Vidas	CE	Negative ≥1.4 Equivocal ≥1 to <1.4 Positive <1	LP/VSER/001

systems						
	CMV IgM		Vidas	CE	Negative <0.7 Equivocal ≥0.7 to <0.9 Positive ≥0.9	LP/VSER/001
	Cytomegalovirus IgM		Manual	CE	< Cut-off (CO) Negative Lower CO to Upper CO Equivocal ≥Upper CO Positive	LP/VSER/075
	Genscreen Ultra HIV Ag/Ab		Manual	CE	≤0.899 Negative 0.900-1.000 Equivocal 1.001-2.999 Weak Positive ≥3.00 Positive	LP/VSER/075
	HAV IgM		Vidas	CE	Negative <0.4 Equivocal ≥0.4 to <0.499 Positive ≥0.500	LP/VSER/001
	HIV screening		Vidas	CE	Negative Ab <0.25 Negative Ag <0.25 Positive Ab ≥0.25 Positive Ag ≥0.25	LP/VSER/001
	Innotest HCV	Serum/Plasma	ELISA	CE Marked Commercial	Neg (-/=0.800, - /=3.000)	LP/VSER/075
	Leptospira IgM	Human serum	Manual	CE	≤0.899 Negative 0.900-1.100 Equivocal 1.101-1.999 Weak Positive ≥2.000 Positive	LP/VSER/075
	Liaison HEV IgM assay	Serum or Plasma	DiaSorin Liaison® XL	CE	Negative =<0.649, Equivocal 0.650- 0.999, Weak Positive 1.000 - 2.999, Positive >=3.000	LP-VSER-077

Liaison Treponema Screen Assay	Serum and plasma	Diasorin Liaison XL	CE Marked	Qualitative	VAL/VSER/166 and LP/VSER/077
Liaison XL Anti-HBc assay	Serum/Plasma	Chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis B core antigen (anti-HBc) in human serum or plasma samples	CE	Samples with anti-HBc levels between an index value of $\geq 0.300$ -0.900 are graded weak positive. Samples with an index value of 0.300 are graded positive	The manufacturer's direction circular and the NVRL procedure LP/VSER/077 Operation and Maintenance of the Diasorin Liaison XL
Liaison XL Murex Anti-HDV Assay	Serum and plasma	Diasorin Liaison XL	CE Marked	Qualitative	VAL/VSER/162 and LP/VSER/077
Measles IgM	Human serum and plasma	Manual	CE	Serum $\leq 0.899$ Negative 0.900-1.099 Equivocal 1.100-1.999 Weak Positive $\geq 2.000$ Positive	LP/VSER/075
Monolisa HCV Ab	Human serum and plasma	Manual	CE	$\leq 0.899$ Negative 0.900-1.000 Equivocal 1.001-2.999 Weak Positive $\geq 3.00$ Positive	LP/VSER/075
Mumps IgG		Diasorin Liaison XL	CE	Negative $\leq 9$ Equivocal $\geq 9.0$ to $\leq 10.99$ Weak positive $\geq 11.0$ to $\leq 49.99$ Positive $\geq 50$	LP/VSER/077
Mumps IgM	Human serum and plasma	Manual	CE	Serum $< 0.856$ Negative $\geq 0.856 - < 1.000$ Equivocal $\geq 1.000 - < 2.000$ Weak Positive	LP/VSER/075

				≥2.000 Positive	
Murex HBsAg	Human serum and plasma	Manual	CE	≤0.899 Negative 0.9 – 1.000 Equivocal 1.001-2.999 Weak Positive ≥3.000 Positive	LP/VSER/075
Murex HBsAg Confirmatory		Manual	CE	Positive/Negative	LP/VSER/075
Murex HTLV I/II		Manual	CE	≤0.899 Negative 0.900-1.000 Equivocal 1.001-2.999 Weak Positive ≥3.00 Positive	LP/VSER/075
Ortho HCV		Manual	CE	≤0.899 Negative 0.900-1.000 Equivocal 1.001-2.999 Weak Positive ≥3.00 Positive	LP/VSER/075
Syphilis IgM		Manual	CE	≤0.899 Negative 0.9-1.000 Equivocal 1.001-1.999 Weak Positive ≥2.000 Positive	LP/VSER/075
Toxo IgG II		Vidas	CE	Negative <4 Equivocal ≥4 to <8 Positive ≥8	LP/VSER/001
Toxo IgM		Vidas	CE	Negative <0.55 Equivocal ≥0.55 to <0.65 Positive ≥6.5	LP/VSER/001
VIDAS Anti-HEV IgM assay	Serum and plasma	BioMerieux VIDAS	CE	Positive Negative	LP-VSER-001
VIDAS CMV IgG	Serum	BioMerieux VIDAS	CE Marked	Quantitative	LP/VSER/001

	Assay					
	Vidas HIV 1 P24 11 Confirmatory	Human serum and plasma	Vidas	CE	Neutralisation % ≥60% p24 antigen confirmed ≤60% negative	LP/VSER/001
1018 Detection of antibody response to infection using appropriate CE marked commercial techniques - .04 Line immunoassay, using CE marked commercial systems	INNO-LIA HCV Score		AUTO-LIA	CE	Negative Indeterminate Positive	LP/VSER/016
	INNO-LIA HIV I/II		Immunoblot	CE	Negative Indeterminate Positive	LP/VSER/016
	INNO-LIA HTLV I/II Score		AUTO-LIA	CE	Negative Indeterminate Positive	LP/VSER/016
	The INNO-LIA Syphilis Score	Serum	Auto Lia 48 Instrument	CE Marked	Positive, Negative, Indeterminate	LP-VSER-016
1018 Detection of antibody response to infection using appropriate CE marked commercial techniques - .07 Chemiluminescent microparticle immunoassay, using CE marked commercial systems	Anti-HBc IgM	Human serum and plasma	Architect i4000	CE	S/CO ≤ 0.999 Negative S/CO 1.000 – 2.999 Weak Positive S/CO ≥ 3.000 Positive	LP/VSER/050
	Anti-HBc II		Architect i4000	CE	S/CO ≤ 0.899 Negative S/CO 0.900 - 1.000 Equivocal S/CO 1.001 - 1.999 Weak Positive S/CO ≥ 2.000 Positive	LP/VSER/050
	Anti-HBe		Architect i4000	CE	S/CO ≥ 1.101	LP/VSER/050

				Negative S/CO 1.002 - 1.100 Equivocal S/CO 0.800 - 1.001 Weak Positive S/CO ≤ 0.800 Positive	
Anti-HBs		Architect i4000	CE	0.0 - 0.49 mIU/ml No antibodies detected 0.50 – 9.99 mIU/ml Less than 10 mIU/ml ≥ 10 mIU/mL mIU/ml value reported	LP/VSER/050
		Diasorin Liaison XL	CE	≤10 IU/ml 10.1-99.9 mIU/ml ≥100 IU/ml	LP/VSER/077
Anti-HCV		Architect i4000	CE	S/CO ≤ 0.799 Negative S/CO 0.800 - 1.000 Equivocal S/CO 1.001 - 4.999 Weak Positive S/CO ≥ 5.000 Positive	LP/VSER/050
Borrelia IgG		Diasorin Liaison XL	CE	Negative ≤9.99 Equivocal ≥10.0 to ≤14.99 Weak positive ≥15.0 to ≤29.99 Positive ≥30	LP/VSER/077
CMV IgG		Architect i4000	CE	≤ 5.999 AU/mL Negative 6.000 – 14.999 AU/mL Weak Positive ≥ 15.000 AU/mL Positive	LP/VSER/050
CMV IgM		Architect i4000	CE	Index ≤ 0.849	LP/VSER/050

					Negative Index 0.850 – 0.999 Equivocal Index 1.000 – 1.999 Weak Positive Index $\geq 2.000$ Positive	
EBNA IgG		Diasorin Liaison XL	CE		Negative $\leq 4.99$ Equivocal $\geq 5.00$ to $\leq 20.00$ Weak positive $\geq 20.01$ to $\leq 30.00$ Positive $\geq 30.01$	LP/VSER/077
EBV IgM		Diasorin Liaison XL	CE		Negative $\leq 19.9$ Equivocal $\geq 20.0$ to $\leq 39.9$ Weak Positive $\geq 40.0$ to $\leq 79.9$ Positive $\geq 80$	LP/VSER/077
EBV VCA IgG		Diasorin Liaison XL	CE		Negative $\leq 19.9$ Equivocal $\geq 20.0$ to $\leq 29.9$ Weak positive $\geq 30.0$ to $\leq 39.9$ Positive $\geq 40$	LP/VSER/077
HAVAb-IgG		Architect i4000	CE		S/CO $\leq 0.899$ Negative S/CO 0.900 - 1.000 Equivocal S/CO 1.001 - 1.999 Weak Positive S/CO $\geq 2.000$ Positive	LP/VSER/050
HAVAb-IgM		Architect i4000	CE		S/CO $\leq 0.799$ Negative S/CO 0.800 - 1.199 Equivocal S/CO 1.200 – 2.999 Weak Positive	LP/VSER/050

				S/CO ≥ 3.000 Positive	
HBeAg		Architect i4000	CE	S/CO ≤ 0.899 Negative S/CO 0.900 - 1.000 Equivocal S/CO 1.001 - 1.100 Weak Positive S/CO ≥1.101 Positive	LP/VSER/050
HBsAg		Architect i4000	CE	S/CO ≤ 0.799 Negative S/CO 0.800 - 1.000 Equivocal S/CO 1.001 - 14.999 Weak Positive S/CO ≥ 15.000 Positive	LP/VSER/050
HCV Ag		Architect i4000	CE	0.000 – 2.999 fmol/L Negative 3.000 – 9.999 fmol/L Weak Positive ≥ 10.000 fmol/L Positive	LP/VSER/050
HIV Ag/Ab Combo		Architect i4000	CE	S/CO ≤ 0.799 Negative S/CO 0.800 - 1.000 Equivocal S/CO 1.001 – 14.999 Weak Positive S/CO ≥15.000 Positive	LP/VSER/050
HSV 1 / 2 IgG	Human serum	Diasorin Liaison XL	CE	Negative ≤0.89 Equivocal ≥0.9 to ≤1.09 Weak positive ≥1.10 to ≤1.49 Positive ≥1.5	LP/VSER/077

Liaison XL Murex recHTLV-I/II assay	Serum/Plasma	Chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to Human T-cell Lymphotropic Virus (HTLV) Type I and Type II (anti-HTLV I and anti-HTLV II) in human serum and plasma samples	CE	Specimens with signal-to-cut-off (S/CO) ratios <1.00 are considered non-reactive for HTLV I/II antibodies. Specimens with signal-to-cut-off (S/CO) ratios of $\geq 1.00$ -2.99 are wk positive and $\geq 3.00$ are considered positive for HTLV I/II antibodies	The manufacturer's direction circular and the NVRL procedure LP/VSER/077 Operation and Maintenance of the Diasorin Liaison XL
Measles IgG	Human serum and plasma	Diasorin Liaison XL	CE	Negative <13.5 Equivocal $\geq 13.5$ to $\leq 16.49$ Weak Positive $\geq 16.5$ to $\leq 49.99$ Positive $\geq 50$	LP/VSER/077
Parvovirus B19 IgG		Diasorin Liaison XL	CE	Negative <0.9 Equivocal $\geq 0.9$ to <1.1 Weak positive $\geq 1.1$ to <1.5 Positive $\geq 1.5$	LP/VSER/077
Parvovirus B19 IgM		Diasorin Liaison XL	CE	Negative <0.9 Equivocal $\geq 0.9$ to <1.1 Weak positive $\geq 1.1$ to <1.5 Positive $\geq 1.5$	LP/VSER/077
rHTLV-I/II		Architect i4000	CE	S/CO $\leq 0.799$ Negative S/CO 0.800 - 1.000 Equivocal S/CO 1.001 - 1.999 Weak Positive S/CO $\geq 2.000$ Positive	LP/VSER/050
Rubella IgG		Architect i4000	CE	$\leq 4.999$ IU/ml No antibodies detected	LP/VSER/050

					5.000 – 14.999 IU/ml As per algorithm ≥ 15.000 IU/mL Greater than 15 IU/ml	
			Diasorin Liaison XL	CE	Less than 5 IU/ml <5 IU/ml Detected at low level ≥5.1 to ≤9.999 IU/ml Greater than 10IU/ml ≥10 IU/ml	LP/VSER/077
	Rubella IgM		Architect i4000	CE	S/CO ≤ 0.749 Negative S/CO 0.750 – 1.000 Equivocal S/CO 1.001 – 1.999 Weak Positive S/CO ≥ 2.000 Positive	LP/VSER/050
	Syphilis TP		Architect i4000	CE	S/CO ≤ 0.499 Negative S/CO 0.500 - 1.000 Equivocal S/CO 1.001 - 3.999 Weak Positive S/CO ≥ 4.000 Positive	LP/VSER/050
	Toxo IgM		Architect i4000	CE	S/CO ≤ 0.829 Negative S/CO 0.830 – 0.999 Equivocal S/CO 1.000 – 1.499 Weak Positive S/CO ≥ 1.500 Positive	LP/VSER/050
	ToxoIgG		Architect i4000	CE	≤ 1.599 IU/ml Negative 1.600 – 2.999 IU/mL Equivocal ≥ 3.000 IU/mL Positive	LP/VSER/050

## NVRL Satellite Laboratory Backweston (NSLB)

### Microbiology and Virology

Category: A

Medical pathology field - Test	Test/assay	Specimen Type	Equipment/Technique	Method (CE/Non-CE/In house developed/based on standard method)	Range of measurement	Std. ref & SOP
1015 Detection and/or identification of bacterial, parasite, fungal and viral nucleic acids - .03 Nucleic acid amplification tests, CE marked commercial systems	ARIES SARS-CoV-2	Respiratory Swabs	Luminex® ARIES® System	CE	Detected/Not Detected	LP-NSLB-013